Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2

被引：3

作者：

Kaieda, Akira ^{[1
]}

Takahashi, Masashi ^{[1
]}

Fukuda, Hiromi ^{[1
]}

Okamoto, Rei ^{[1
]}

Morimoto, Shinji ^{[1
]}

Gotoh, Masayuki ^{[1
]}

Miyazaki, Takahiro ^{[1
]}

Hori, Yuri ^{[1
]}

Unno, Satoko ^{[1
]}

Kawamoto, Tomohiro ^{[1
]}

Tanaka, Toshimasa ^{[1
]}

Itono, Sachiko ^{[1
]}

Takagi, Terufumi ^{[1
]}

Sugimoto, Hiroshi ^{[1
]}

Okada, Kengo ^{[1
]}

Lane, Weston ^{[2
]}

Sang, Bi-Ching ^{[2
]}

Saikatendu, Kumar ^{[2
]}

Matsunaga, Shinichiro ^{[1
]}

Miwatashi, Seiji ^{[1
]}

机构：

[1] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, 26-1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 2518555, Japan

[2] Takeda Calif, 10410 Sci Ctr Dr, San Diego, CA 92121 USA

来源：

CHEMMEDCHEM | 2019年 / 14卷 / 24期

基金：

美国国家卫生研究院;

关键词：

p38 mitogen-activated protein kinase inhibitors; rheumatoid arthritis; structure-based design; imidazo[4; 5-b]pyridin-2-one derivatives; ACTIVATED PROTEIN-KINASE; RHEUMATOID-ARTHRITIS; ANTIRHEUMATIC DRUGS; DOUBLE-BLIND; ALPHA; DISCOVERY; POTENT; EXPRESSION; ANTIBODY; PATHWAY;

D O I：

10.1002/cmdc.201900373

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We identified novel potent inhibitors of p38 mitogen-activated protein (MAP) kinase using a structure-based design strategy, beginning with lead compound, 3-(butan-2-yl)-6-(2,4-difluoroanilino)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (1). To enhance the inhibitory activity of 1 against production of tumor necrosis factor-alpha (TNF-alpha) in human whole blood (hWB) cell assays, we designed and synthesized hybrid compounds in which the imidazo[4,5-b]pyridin-2-one core was successfully linked with the p-methylbenzamide fragment. Among the compounds evaluated, 3-(3-tert-butyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-4-methyl-N-(1-methyl-1H-pyrazol-3-yl)benzamide (25) exhibited potent p38 inhibition, superior suppression of TNF-alpha production in hWB cells, and also significant in vivo efficacy in a rat model of collagen-induced arthritis (CIA). In this paper, we report the discovery of potent, selective, and orally bioavailable imidazo[4,5-b]pyridin-2-one-based p38 MAP kinase inhibitors.

引用

页码：2093 / 2101

页数：9

共 34 条

[1] Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases
Albrecht, Wolfgang
Unger, Anke
Bauer, Silke M.
Laufer, Stefan A.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (13) : 5290 - 5305
[2] Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity
Angell, Richard
Aston, Nicola M.
Bamborough, Paul
Buckton, Jacky B.
Cockerill, Stuart
deBoeck, Suzanne J.
Edwards, Chris D.
Holmes, Duncan S.
Jones, Katherine L.
Laine, Dramane I.
Patel, Shila
Smee, Penny A.
Smith, Kathryn J.
Somers, Don O.
Walker, Ann L.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (15) : 4428 - 4432
[3] p38α Mitogen-Activated Protein Kinase Inhibitors: Optimization of a Series of Biphenylamides to Give a Molecule Suitable for Clinical Progression
Aston, Nicola M.
Bamborough, Paul
Buckton, Jacqueline B.
Edwards, Christopher D.
Holmes, Duncan S.
Jones, Katherine L.
Patel, Vipulkumar K.
Smee, Penny A.
Somers, Donald O.
Vitulli, Giovanni
Walker, Ann L.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (20) : 6257 - 6269
[4] Adalimumab - A review of its use in rheumatoid arthritis
Bang, LM
Keating, GM
[J]. BIODRUGS, 2004, 18 (02) : 121 - 139
[5] The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor
Duffy, John P.
Harrington, Edmund M.
Salituro, Francesco G.
Cochran, John E.
Green, Jeremy
Gao, Huai
Bemis, Guy W.
Evindar, Ghotas
Galullo, Vincent P.
Ford, Pamella J.
Germann, Ursula A.
Wilson, Keith P.
Bellon, Steven F.
Chen, Guanging
Taslimi, Paul
Jones, Peter
Huang, Cassey
Pazhanisamy, S.
Wang, Yow-Ming
Murcko, Mark A.
Su, Michael S. S.
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (10): : 758 - 763
[6] RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS
ELLIOTT, MJ
MAINI, RN
FELDMANN, M
KALDEN, JR
ANTONI, C
SMOLEN, JS
LEEB, B
BREEDVELD, FC
MACFARLANE, JD
BIJL, H
WOODY, JN
[J]. LANCET, 1994, 344 (8930) : 1105 - 1110
[7] Goldstein DM, 2010, J MED CHEM, V53, P2345, DOI [10.1021/acs.jmedchem.8b00124, 10.1021/jm9012906]
[8] Pathway to the clinic: Inhibition of p38 MAP kinase. A review of ten chemotypes selected for development
Goldstein, DM
Gabriel, T
[J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (10) : 1017 - 1029
[9] Hale KK, 1999, J IMMUNOL, V162, P4246
[10] Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO

← 1 2 3 4 →